181 related articles for article (PubMed ID: 6613192)
1. [Beta 2 glycoprotein I analysis in patients with hyperlipoproteinemia, arteriosclerotic occlusive disease and diabetes mellitus].
Müller G; Biering A; Lux E; Richter V
Z Gesamte Inn Med; 1983 May; 38(10):282-4. PubMed ID: 6613192
[TBL] [Abstract][Full Text] [Related]
2. [Composition of VLDL, LDL and HDL lipoprotein fractions in type IIa, IIb, III, IV, and V hyperlipemia patients in comparison with healthy individuals].
Hutt V; Klör HU; Wechsler JG; Ditschuneit H
J Clin Chem Clin Biochem; 1984 Feb; 22(2):141-6. PubMed ID: 6716054
[TBL] [Abstract][Full Text] [Related]
3. [HDL, HDL2 and HDL3 cholesterol in various types of hyperlipoproteinemia in relation to clinical signs of arteriosclerosis].
Sznajderman M; Zawadzki Z
Kardiol Pol; 1986; 29(3):194-203. PubMed ID: 3773408
[No Abstract] [Full Text] [Related]
4. Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks.
Otto C; Ritter MM; Richter WO; Minkenberg R; Schwandt P
Metabolism; 2001 Feb; 50(2):166-70. PubMed ID: 11229424
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of the effects of fenofibrate administered in doses of 3 x 100mg and 1 x 250mg per day in patients with type IIA, IIB and IV hyperlipoproteinemias].
Reiner Z; Salzer B; Kes P
Acta Med Iugosl; 1988; 42(5):353-62. PubMed ID: 3245481
[No Abstract] [Full Text] [Related]
6. [Fibrinolytic capacity after exertion in atherogenic hyperlipoproteinemias].
Zdrenghea D; Mărcuşu C; Cucuianu M; Rentsch S
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1979; 31(5):435-40. PubMed ID: 44567
[No Abstract] [Full Text] [Related]
7. [Immunochemical study of the alpha 2-glycoprotein from the atherosclerotically altered aortic wall in the blood serum of ischemic heart disease patients].
Murashko VV; Baranov AP; Kamenets AV; Tatarinov IuS; Chekhonin VP
Ter Arkh; 1985; 57(9):37-9. PubMed ID: 2417347
[TBL] [Abstract][Full Text] [Related]
8. [Platelet half-life in patients with primary hyperlipoproteinemia type IIa, IIb, and IV according to Fredrickson with and without clinical signs of atherosclerosis].
Jäger E; Sinzinger H; Widhalm K; Kaliman J; Höfer R
Wien Klin Wochenschr; 1982 Sep; 94(16):421-5. PubMed ID: 7147981
[TBL] [Abstract][Full Text] [Related]
9. Determination of anti-elastin peptide antibodies in normal and arteriosclerotic human sera by ELISA.
Fulop T; Jacob MP; Robert L
J Clin Lab Immunol; 1989 Oct; 30(2):69-74. PubMed ID: 2641531
[TBL] [Abstract][Full Text] [Related]
10. Very low density lipoprotein (VLDL) pattern in primary hyperlipoproteinaemia type IIb and type IV.
Kłosiewicz-Latoszek L; Naruszewicz M; Cybulska B; Szostak WB; Chotkowska E
Mater Med Pol; 1979; 11(3):230-4. PubMed ID: 232894
[No Abstract] [Full Text] [Related]
11. [Platelet aggregation in hyperlipoproteinemias].
Calabrese S; Da Col PG; Giansante C; Morgante O; Cattin L
Minerva Med; 1982 May; 73(22):1541-6. PubMed ID: 7088380
[TBL] [Abstract][Full Text] [Related]
12. Oxidative burst and lysosomal enzyme release by polymorphonuclear cells in type IIa, type IIb and type IV primary hyperlipoproteinaemia.
Ventura MT; Puzziferri I; Tortorella C; Resta F; Capurso A; Antonaci S
Recenti Prog Med; 1993; 84(7-8):503-10. PubMed ID: 8356303
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of coagulation, atherosclerosis, and arterial thrombosis.
Conard J; Samama MM
Semin Thromb Hemost; 1986 Apr; 12(2):87-90. PubMed ID: 3755552
[No Abstract] [Full Text] [Related]
14. Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.
Bonora V; Calalabuig RJ; Caviola E; Soler J; Pueyo JM; Micaló T; Cano RP
Clin Ther; 1981; 4(3):192-200. PubMed ID: 7030489
[TBL] [Abstract][Full Text] [Related]
15. Behaviour of platelet adhesiveness and of dilute clot blood lysis time in hyperlipoproteinemic subjects.
Zdrenghea D; Stef C; Cucuianu M; Vlaicu R
Med Interne; 1979; 17(3):273-7. PubMed ID: 504931
[No Abstract] [Full Text] [Related]
16. [Behavior of serum lipids, blood coagulation factors, platelet aggregation, complement and serum immunoglobulins in a group of arteriosclerotic, hyperlipemic subjects treated with 3GS].
D'Eredità F; Avellone G; Novo S; Davì G; Abruzzese G; Di Liberti M; Pinto A; Riolo F
Clin Ter; 1981 Feb; 96(3):303-24. PubMed ID: 7307448
[No Abstract] [Full Text] [Related]
17. Pirifibrate in the treatment of hyperlipoproteinemias: a multicenter study.
Domingo AJ; Gutiérrez JA; Menéndez JA; Micó L; Muñoz M; de Oya M
Clin Ther; 1980; 3(3):219-26. PubMed ID: 7459931
[TBL] [Abstract][Full Text] [Related]
18. Determination of elastin peptides in normal and arteriosclerotic human sera by ELISA.
Fülöp T; Wei SM; Robert L; Jacob MP
Clin Physiol Biochem; 1990; 8(6):273-82. PubMed ID: 2132161
[TBL] [Abstract][Full Text] [Related]
19. [Effect of acipimox on diabetes mellitus-associated hyperlipoproteinemia].
Paragh G; Balogh Z; Boda J; Mohácsi A; Juhász A; Leövey A
Orv Hetil; 1993 Jan; 134(3):121-4. PubMed ID: 8421622
[TBL] [Abstract][Full Text] [Related]
20. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
Hutt V; Wechsler JG; Klör HU; Ditschuneit H
Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
